{"product_id":"comparing-surgical-routes-for-robotic-prostate-cancer-surgery-extraperitoneal-vs-transperitoneal-single-port-approaches","title":"Comparing Surgical Routes for Robotic Prostate Cancer Surgery: Extraperitoneal vs. Transperitoneal Single-Port Approaches","description":"\u003cp\u003eThis meta-analysis compared two surgical routes for single-port robot-assisted radical prostatectomy (SP-RARP), a minimally invasive surgery for prostate cancer. Researchers analyzed data from 833 patients across 5 studies and found that the transperitoneal approach (entering through the abdominal cavity) resulted in less blood loss, fewer serious complications, and better urinary continence recovery, while the extraperitoneal approach (working outside the abdominal cavity) led to shorter hospital stays. Both techniques proved safe and effective, with no significant differences in operation time, pain scores, or positive surgical margin rates.\u003c\/p\u003e\n\n\u003ch1\u003eComparing Surgical Routes for Robotic Prostate Cancer Surgery: Extraperitoneal vs. Transperitoneal Single-Port Approaches\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: What the Study Discovered\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality\"\u003eQuality and Reliability of the Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eBoth extraperitoneal and transperitoneal single-port robotic prostatectomy are safe and effective for localized prostate cancer.\u003c\/li\u003e\n\u003cli\u003eTransperitoneal approach resulted in less blood loss, fewer serious complications, and better urinary continence recovery at 90 days.\u003c\/li\u003e\n\u003cli\u003eExtraperitoneal approach led to shorter hospital stays, with patients discharged about 8 hours earlier on average.\u003c\/li\u003e\n\u003cli\u003eNo significant differences were found between approaches for operation time, pain scores, or positive surgical margins.\u003c\/li\u003e\n\u003cli\u003eThe choice of approach should be individualized, considering surgeon experience, patient factors, and recovery priorities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer is one of the most common cancers in men, and surgery to remove the prostate gland — called \u003cstrong\u003eradical prostatectomy\u003c\/strong\u003e — remains a cornerstone of treatment for localized disease. In recent years, \u003cstrong\u003erobot-assisted radical prostatectomy (RARP)\u003c\/strong\u003e has become a leading surgical approach because it offers greater precision, smaller incisions, and faster recovery than traditional open surgery.\u003c\/p\u003e\n\n\u003cp\u003eThe newest advancement in this field is \u003cstrong\u003esingle-port (SP) robotic surgery\u003c\/strong\u003e, which was approved in the United States in 2018. Unlike traditional multiport robotic surgery that requires several incisions, single-port surgery uses just one small entry point. This approach offers a compact design, minimal trauma, and dual cameras, making it an increasingly popular alternative to conventional multiport RARP.\u003c\/p\u003e\n\n\u003cp\u003eSurgeons can perform SP-RARP using two different routes to reach the prostate:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe transperitoneal approach (SP-TPRP):\u003c\/strong\u003e The surgeon enters through the abdominal cavity (peritoneum), similar to traditional laparoscopic surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe extraperitoneal approach (SP-EPRP):\u003c\/strong\u003e The surgeon works in the space outside the abdominal cavity (the extraperitoneal space), without entering the peritoneum.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere has been ongoing debate among surgeons about which approach is better. Some argue that extraperitoneal surgery reduces operation time, blood loss, and hospital stays while lowering the risk of positive surgical margins (cancer cells remaining at the edge of the removed tissue) and complications. Others believe the transperitoneal route provides a better surgical view, enhanced precision, and greater protection of the urethra and surrounding nerves.\u003c\/p\u003e\n\n\u003cp\u003ePrevious analyses of traditional multiport robotic surgery suggested that the extraperitoneal approach offered faster operation times, shorter hospital stays, and fewer complications. However, until now, no study had systematically compared these two approaches specifically for single-port robotic surgery. This research was designed to fill that gap and help surgeons choose the best approach for their patients.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers followed the \u003cstrong\u003ePreferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)\u003c\/strong\u003e guidelines, which are internationally recognized standards for conducting and reporting research reviews. The study was registered in advance with PROSPERO, an international database for systematic reviews, under registration number CRD42023409667.\u003c\/p\u003e\n\n\u003cp\u003eA systematic search of four major medical databases — \u003cstrong\u003ePubMed, Embase, Web of Science, and the Cochrane Library\u003c\/strong\u003e — was conducted to identify all relevant studies published up to February 2023. The search used combinations of keywords such as \"transperitoneal radical prostatectomy,\" \"extraperitoneal radical prostatectomy,\" \"robotic surgical procedures,\" and \"single port.\" The researchers also manually reviewed reference lists of relevant papers to ensure no important studies were missed.\u003c\/p\u003e\n\n\u003cp\u003eStudies were selected based on strict criteria:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients:\u003c\/strong\u003e Men diagnosed with localized prostate cancer\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntervention:\u003c\/strong\u003e Extraperitoneal single-port robot-assisted radical prostatectomy\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComparison:\u003c\/strong\u003e Transperitoneal single-port robot-assisted radical prostatectomy\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutcomes:\u003c\/strong\u003e At least one measure of perioperative outcomes (surgery-related), functional outcomes (urinary continence), or oncological outcomes (positive surgical margins)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStudy design:\u003c\/strong\u003e Case-control studies, cohort studies, or randomized controlled trials\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eStudies were excluded if they were conference reports, editorials, conference abstracts, non-comparative research, or lacked analyzable data.\u003c\/p\u003e\n\n\u003cp\u003eTwo reviewers independently extracted data from each study, including patient characteristics (age, body mass index, PSA levels, prostate size, tumor stage), perioperative outcomes (operation time, hospital stay, blood loss, pain scores), complications, continence recovery, and positive surgical margin rates. Any disagreements were resolved by a third reviewer.\u003c\/p\u003e\n\n\u003cp\u003eFor statistical analysis, the researchers used \u003cstrong\u003eStata 15.1 software\u003c\/strong\u003e. Results for yes\/no outcomes were expressed as \u003cstrong\u003erisk ratios (RR)\u003c\/strong\u003e, while continuous outcomes (like blood loss or hospital days) were expressed as \u003cstrong\u003eweighted mean differences (WMD)\u003c\/strong\u003e, both with 95% confidence intervals. Statistical heterogeneity — variation between studies — was measured using the I² statistic. When I² was 50% or higher, indicating significant heterogeneity, a random-effects model was used; when below 50%, a fixed-effects model was applied. Sensitivity analyses were performed using the \"leave-one-out\" method, which removes one study at a time to verify that no single study was driving the results.\u003c\/p\u003e\n\n\u003cp\u003eStudy quality was assessed using the \u003cstrong\u003eNewcastle–Ottawa Scale (NOS)\u003c\/strong\u003e, a widely used tool that rates studies on participant selection, comparability of groups, and outcome assessment. Studies scoring below 5 points were excluded.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: What the Study Discovered\u003c\/h2\u003e\n\n\u003cp\u003eAfter screening 318 studies from the four databases, the researchers identified \u003cstrong\u003e5 studies that met all inclusion criteria\u003c\/strong\u003e. These were prospective or retrospective cohort studies conducted in the United States, involving a total of \u003cstrong\u003e833 patients — 425 who underwent SP-TPRP and 408 who underwent SP-EPRP\u003c\/strong\u003e. Individual study sizes ranged from 34 to 476 patients.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the two patient groups were well-matched at the start of the studies. There were no statistically significant differences between groups in age (p = 0.957), body mass index (p = 0.054), preoperative PSA levels (p = 0.139), history of previous abdominal surgery (p = 0.394), biopsy grade (p = 0.995), or prostate volume (p = 0.458). This means that differences in outcomes could be attributed to the surgical approach rather than to pre-existing differences between patients.\u003c\/p\u003e\n\n\u003ch3\u003eOperative Time: No Significant Difference\u003c\/h3\u003e\n\n\u003cp\u003eAll 5 studies reported operative time for both approaches. The meta-analysis found \u003cstrong\u003eno statistically significant difference\u003c\/strong\u003e in operation time between SP-EPRP and SP-TPRP (WMD: 3.02 minutes, 95% CI −32.49 to 38.52; p = 0.868).\u003c\/p\u003e\n\n\u003cp\u003eThis finding differs from earlier research on multiport robotic surgery. For example, a previous study by Uy and colleagues found that extraperitoneal surgery had a shorter operation time than transperitoneal surgery in multiport RARP, because it reaches the prostate directly without passing through the abdominal cavity. The researchers suggest several possible reasons for this difference in single-port surgery:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgeon experience:\u003c\/strong\u003e Two of the included studies reported that surgeons were more experienced with SP-TPRP and less familiar with SP-EPRP, which could have lengthened SP-EPRP operation times.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient body mass index (BMI):\u003c\/strong\u003e Higher BMI and thicker abdominal wall fat make surgery more difficult and time-consuming. This is especially true in transperitoneal surgery with the patient in the Trendelenburg position (head-down tilt).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers note that if these factors were controlled, SP-EPRP might show a time advantage, as seen in multiport surgery.\u003c\/p\u003e\n\n\u003ch3\u003eBlood Loss: SP-TPRP Came Out Ahead\u003c\/h3\u003e\n\n\u003cp\u003eFive studies reported intraoperative blood loss, and the results significantly favored the transperitoneal approach. Patients in the SP-TPRP group lost, on average, \u003cstrong\u003e43.92 milliliters less blood\u003c\/strong\u003e during surgery than SP-EPRP patients (WMD: −43.92, 95% CI −69.81 to −18.04; p = 0.001). This difference was statistically significant, meaning there is strong evidence it is a real effect and not due to chance.\u003c\/p\u003e\n\n\u003ch3\u003eHospital Stay: SP-EPRP Got Patients Home Sooner\u003c\/h3\u003e\n\n\u003cp\u003eFour studies reported on hospital stay duration, and here the extraperitoneal approach had the advantage. Patients in the SP-EPRP group were discharged on average \u003cstrong\u003e7.88 hours (roughly one-third of a day) earlier\u003c\/strong\u003e than SP-TPRP patients (WMD: 7.88, 95% CI 0.65 to 15.10; p = 0.03).\u003c\/p\u003e\n\n\u003cp\u003eThe researchers explain that the longer hospital stay with SP-TPRP may be related to peritoneal irritation and intestinal obstruction (blockage), which can occur when the abdominal cavity is entered during surgery. Because SP-EPRP bypasses the intestines, contact with the bowel is greatly reduced, potentially allowing for a quicker recovery and earlier discharge.\u003c\/p\u003e\n\n\u003ch3\u003ePostoperative Pain: Comparable Between Approaches\u003c\/h3\u003e\n\n\u003cp\u003eFour studies assessed pain scores at discharge. There was \u003cstrong\u003eno significant difference\u003c\/strong\u003e between the two groups (WMD −0.08, 95% CI −0.40 to 0.23; p = 0.6). Patients reported similar levels of pain after both procedures, and opioid painkiller requirements were also comparable.\u003c\/p\u003e\n\n\u003ch3\u003eComplications: A Nuanced Picture\u003c\/h3\u003e\n\n\u003cp\u003ePostoperative complications were analyzed in two ways. When looking at the \u003cstrong\u003eoverall complication rate\u003c\/strong\u003e, there was no significant difference between the two approaches (RR 0.92, 95% CI 0.64 to 1.31; p = 0.74).\u003c\/p\u003e\n\n\u003cp\u003eHowever, when the researchers focused on \u003cstrong\u003emore serious complications — defined as Clavien-Dindo grade II or higher\u003c\/strong\u003e (complications requiring medication, surgical intervention, or intensive care) — a different picture emerged. The SP-TPRP group had a \u003cstrong\u003e45% lower risk\u003c\/strong\u003e of these serious complications compared to the SP-EPRP group (RR 0.55, 95% CI 0.31 to 0.99; p = 0.04). This means that while both approaches carry similar overall complication rates, the complications that do occur with SP-TPRP tend to be less severe.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers noted that two of the included studies found a higher rate of \u003cstrong\u003elymphoid cysts (lymphoceles)\u003c\/strong\u003e — fluid collections that can form after pelvic lymph node dissection — in the SP-EPRP group. This may be because while SP-EPRP preserves the intraperitoneal structures, its working space is more limited and lacks the lymphatic channels needed to absorb fluid. Keeping the peritoneal space open during surgery or during lymph node removal may help reduce this complication.\u003c\/p\u003e\n\n\u003ch3\u003eUrinary Continence Recovery: SP-TPRP Had the Edge\u003c\/h3\u003e\n\n\u003cp\u003eFour studies reported on urinary continence recovery at \u003cstrong\u003e90 days after surgery\u003c\/strong\u003e, defined as using no pads or only one safety pad per day. The results significantly favored the transperitoneal approach, with patients in the SP-TPRP group being \u003cstrong\u003e23% more likely\u003c\/strong\u003e to achieve continence recovery at 90 days (RR 1.23, 95% CI 1.05 to 1.45; p = 0.04).\u003c\/p\u003e\n\n\u003cp\u003eThe researchers believe this advantage may stem from SP-TPRP's ability to better protect the urethral sphincter — the muscle that controls urine flow. The transperitoneal route allows better visualization and preservation of the external urethral sphincter and surrounding nerve tissue. The use of \u003cstrong\u003enerve-sparing techniques\u003c\/strong\u003e during surgery was also highlighted as an important factor in continence recovery, along with the surgeon's level of experience.\u003c\/p\u003e\n\n\u003ch3\u003ePositive Surgical Margins: No Difference\u003c\/h3\u003e\n\n\u003cp\u003eFour studies reported on \u003cstrong\u003epositive surgical margins (PSM)\u003c\/strong\u003e — the presence of cancer cells at the edge of the removed prostate tissue, which is associated with a higher risk of cancer recurrence. There was \u003cstrong\u003eno statistically significant difference\u003c\/strong\u003e between the two approaches (RR 1.03, 95% CI 0.80 to 1.32; p = 0.8). Both SP-EPRP and SP-TPRP achieved similar rates of complete cancer removal.\u003c\/p\u003e\n\n\u003ch2 id=\"quality\"\u003eQuality and Reliability of the Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe quality of the five included studies was assessed using the Newcastle–Ottawa Scale. All studies scored \u003cstrong\u003e5 or higher\u003c\/strong\u003e (out of a possible 9), with a median score of 7. Two studies earned a score of 8, two scored 6 or 7, and one scored 5. This indicates generally good methodological quality across the included research.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also examined statistical heterogeneity — how much the results varied between studies. For three outcomes, heterogeneity was high:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHospital stay:\u003c\/strong\u003e I² = 94.0% (very high variation between studies)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOperation time:\u003c\/strong\u003e I² = 96.2% (very high variation)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlood loss:\u003c\/strong\u003e I² = 75.4% (substantial variation)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers conducted meta-regression analyses based on publication year and sample size to explore the sources of this heterogeneity, but these factors did not explain the variation (p \u0026gt; 0.05). Due to the small number of studies, further subgroup analyses could not be performed.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, \u003cstrong\u003esensitivity analyses\u003c\/strong\u003e using the leave-one-out method showed that the results remained consistent when each study was removed in turn. This means no single study was responsible for driving any of the findings, which strengthens confidence in the conclusions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication bias\u003c\/strong\u003e — the tendency for studies with positive results to be published more readily than those with negative results — was also assessed using funnel plots and Begg's regression tests. No evidence of publication bias was found for operative time, blood loss, or hospital stay (p \u0026gt; 0.05), supporting the integrity of the findings.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor men facing prostate cancer surgery, this study offers several important takeaways. Both surgical approaches for single-port robotic prostatectomy are \u003cstrong\u003esafe and effective\u003c\/strong\u003e, giving surgeons and patients flexibility in choosing the best option based on individual circumstances.\u003c\/p\u003e\n\n\u003cp\u003eHere is what the evidence suggests in practical terms:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf faster recovery of urinary control is a priority:\u003c\/strong\u003e The transperitoneal approach (SP-TPRP) appears to offer a better chance of regaining continence by 90 days after surgery. This is a critical quality-of-life consideration for many men after prostatectomy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf minimizing serious complications is the goal:\u003c\/strong\u003e SP-TPRP was associated with fewer Clavien-Dindo grade II and above complications. Patients may be less likely to experience complications requiring medical intervention or readmission.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf reducing blood loss matters:\u003c\/strong\u003e SP-TPRP showed significantly lower intraoperative blood loss, which can contribute to a smoother recovery and reduced need for transfusions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf getting home sooner is important:\u003c\/strong\u003e The extraperitoneal approach (SP-EPRP) was associated with shorter hospital stays, which may be appealing for patients who prefer minimal time in the hospital.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you're concerned about cancer control:\u003c\/strong\u003e Both approaches achieved similar rates of negative surgical margins, meaning cancer control outcomes were comparable.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe choice between these two approaches should be discussed carefully with your surgical team. Factors that may influence the decision include the surgeon's level of experience with each technique, your body mass index, your previous surgical history, and the specific characteristics of your cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eWhile this meta-analysis provides valuable insights, it has several limitations that should be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall number of studies:\u003c\/strong\u003e Only 5 studies met the inclusion criteria, which limits the statistical power of the analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo randomized controlled trials:\u003c\/strong\u003e All included studies were prospective or retrospective cohort studies, which are more susceptible to bias than randomized trials. Patients were not randomly assigned to one approach or the other, so unmeasured factors could have influenced outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeographic limitation:\u003c\/strong\u003e All studies were conducted in the United States, and results may not generalize to other countries with different healthcare systems, surgical training, or patient populations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh heterogeneity:\u003c\/strong\u003e Results for hospital stay, operation time, and blood loss showed considerable variation between studies, which may reflect differences in surgical technique, patient characteristics, or institutional practices.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgeon experience was not uniform:\u003c\/strong\u003e Some surgeons were more experienced with one approach than the other, which could have affected outcomes such as operation time and complication rates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited follow-up duration:\u003c\/strong\u003e Continence was assessed at 90 days, but longer-term outcomes beyond this period were not available in the included studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup analysis not possible:\u003c\/strong\u003e The small number of studies prevented the researchers from conducting meaningful subgroup analyses to explore how factors like BMI, cancer stage, or nerve-sparing technique might influence outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you or a loved one is considering robot-assisted radical prostatectomy, here are some practical recommendations based on this research:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHave an open discussion with your surgeon\u003c\/strong\u003e about which approach — extraperitoneal or transperitoneal — is recommended for your specific situation, and why. Ask about their personal experience with each technique.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider your priorities.\u003c\/strong\u003e If urinary continence recovery is your primary concern, the transperitoneal approach may offer advantages. If you prefer a shorter hospital stay, the extraperitoneal approach may be worth discussing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about nerve-sparing techniques.\u003c\/strong\u003e The study found that nerve preservation during surgery significantly affects continence recovery. Ask your surgeon whether you are a candidate for nerve-sparing surgery, as this can depend on the stage and location of your cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your risk factors.\u003c\/strong\u003e Your BMI, previous abdominal surgeries, and prostate size can all affect surgical outcomes. Be transparent with your surgical team about your medical history.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that both approaches are safe and effective.\u003c\/strong\u003e The most important factor in a good outcome is often the skill and experience of your surgical team, rather than the specific approach used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSet realistic expectations.\u003c\/strong\u003e While this study shows SP-TPRP offers a 23% better chance of continence recovery at 90 days, individual results vary widely. Many men continue to see improvements in continence for up to 12 months after surgery.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe researchers concluded that this study successfully demonstrates that both extraperitoneal and transperitoneal SP-RARP approaches are safe and effective for treating localized prostate cancer. They note that SP-TPRP appears to offer advantages in blood loss, serious complication rates, and continence recovery, although it is accompanied by longer hospital stays. This information provides valuable insights for clinicians selecting the most suitable surgical method for each patient, and for patients themselves, who deserve to be active participants in this important decision.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are the two surgical routes for single-port robotic prostatectomy?\u003c\/h3\u003e\n\u003cp\u003eThey are the transperitoneal approach, which enters through the abdominal cavity, and the extraperitoneal approach, which works outside the abdominal cavity. Both are minimally invasive techniques to remove the prostate for localized prostate cancer. Each route has specific advantages and disadvantages, and both are considered safe and effective options.\u003c\/p\u003e\n\u003ch3\u003eWhich approach leads to a shorter hospital stay?\u003c\/h3\u003e\n\u003cp\u003eThe extraperitoneal approach (SP-EPRP) led to shorter hospital stays. Patients were discharged about 7.88 hours earlier on average than those who had the transperitoneal approach. This may be because the extraperitoneal route avoids the abdominal cavity, potentially allowing faster bowel recovery.\u003c\/p\u003e\n\u003ch3\u003eIs urinary continence recovery better with one approach?\u003c\/h3\u003e\n\u003cp\u003eYes. The transperitoneal approach (SP-TPRP) offered better urinary continence recovery at 90 days after surgery. Patients were 23% more likely to achieve continence, defined as using no pads or only one safety pad per day. Better visualization of the urethral sphincter may explain this advantage.\u003c\/p\u003e\n\u003ch3\u003eDo the two approaches differ in cancer control?\u003c\/h3\u003e\n\u003cp\u003eNo significant difference was found in positive surgical margins, which is the presence of cancer cells at the edge of the removed prostate. Both the extraperitoneal and transperitoneal approaches achieved similar rates of complete cancer removal. So the choice between approaches does not appear to affect this important oncological outcome.\u003c\/p\u003e\n\u003ch3\u003eWhich approach has fewer serious complications?\u003c\/h3\u003e\n\u003cp\u003eThe transperitoneal approach was associated with a 45% lower risk of serious complications, defined as Clavien-Dindo grade II or higher, which require medication, surgery, or intensive care. Overall complication rates were similar, but complications with the transperitoneal approach tended to be less severe.\u003c\/p\u003e\n\u003ch3\u003eHow should I decide which surgical approach is right for me?\u003c\/h3\u003e\n\u003cp\u003eDiscuss with your surgeon which approach fits your situation. Consider your priorities: transperitoneal may offer better continence recovery, less blood loss, and fewer serious complications, but longer hospital stay. Extraperitoneal may allow earlier discharge. Factors like surgeon experience, your BMI, previous abdominal surgeries, and cancer characteristics also matter.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with localized prostate cancer seek a second opinion about the choice between transperitoneal and extraperitoneal single-port robotic prostatectomy?\u003c\/h3\u003e\n\u003cp\u003eIn localized prostate cancer, both single-port robotic surgical routes are safe and effective, but they differ in trade-offs: the transperitoneal route has less blood loss, fewer serious complications, and better 90-day urinary continence recovery, while the extraperitoneal route allows a shorter hospital stay. A second opinion can help you weigh these differences against your priorities, confirm that the recommended approach fits your cancer characteristics, and ensure you have explored nerve-sparing options. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Perioperative, function, and positive surgical margin in extraperitoneal versus transperitoneal single port robot-assisted radical prostatectomy: a systematic review and meta-analysis\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Jiang Y, Liu Y, Qin S, Zhong S, Huang X.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e World Journal of Surgical Oncology (2023) 21:383\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1186\/s12957-023-03272-7\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegistration:\u003c\/strong\u003e PROSPERO (CRD 42023409667)\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace individualized medical advice from your healthcare provider. Always discuss your specific treatment options with your urologist or surgeon.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47527647903900,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/comparing-surgical-routes-for-robotic-prostate-cancer-surgery-extraperitoneal-vs-transperitoneal-single-port-approaches","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}